Evidence map›Paper›PMID 39253927›Full record

ArticleCurrent medicinal chemistry2025

Cell Polarity-related Gene PTK7, a Potential Diagnostic Biomarker in Pan-cancer.

Yuzhe Zhang, Lirong Yan, Aoran Liu, Fang Li, Yanke Li, Ye Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuzhe ZhangThe First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China.
Lirong YanThe First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China.
Aoran LiuThe First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China.
Fang LiThe First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China.
Yanke LiDepartment of Anorectal Surgery, the First Hospital of China Medical University, Shenyang, 110001, China.
Ye ZhangThe First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China.

Funding

National Natural Science Foundation of China 82073244
6 · The paper itself

Abstract

backgroundPTK7 (Protein Tyrosine Kinase 7), a member of the receptor protein tyrosine kinase family, was originally discovered in colon cancer cells. It plays a pivotal role in numerous developmental and physiological processes, particularly in the regulation of cell polarity. Despite accumulating evidence of PTK7's significant influence on tumor development, a comprehensive pan-cancer analysis of PTK7 has yet to be conducted.

methodsWe conducted a comprehensive analysis of PTK7's expression, prognostic value, and mutational patterns across various tumor types. We further explored the correlations between PTK7 expression and tumor stemness, immune-related genes, immune scores, and immune cell infiltration.

resultsEnrichment analysis revealed PTK7's critical involvement in pan-cancer functions and processes, including the WNT pathway, Epithelial-Mesenchymal Transition (EMT), and cell polarity regulation. Additionally, we validated PTK7's expression in gastric cancer via immunohistochemistry.

conclusionOur study indicates that PTK7 holds promise as an ideal pan-cancer biomarker due to its involvement in tumor progression and tumor immunity.

Indexed as

Biomarkers, TumorCell Adhesion MoleculesCell PolarityNeoplasmsReceptor Protein-Tyrosine KinasesEpithelial-Mesenchymal TransitionHumansBiomarkers, TumorCell Adhesion MoleculesPTK7 protein, humanReceptor Protein-Tyrosine Kinasesimmune infiltration.multi-omicspan-cancerprognosisPTK7tumor microenvironment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.